+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Mantle Cell Lymphoma

  • ID: 4846135
  • Report
  • January 2021
  • Region: Global
  • 50 pages
  • Datamonitor Healthcare
This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to 18,010 incident cases by 2026.

It is estimated that the majority of diagnosed cases were male in 2017.

The incidence of MCL is highest among older individuals aged 60+ years. Approved drugs in the MCL space focus on a wide variety of targets. The majority of these drugs are administered via the oral or intravenous route, with one product also being available in a subcutaneous formulation.

The majority of industry-sponsored drugs in active clinical development for MCL are in Phase II. Therapies in active clinical development for MCL focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the MCL space comprise topline Phase II/III trial results for umbralisib, and topline Phase III trial results for Venclexta, Imbruvica, and Calquence.

The overall likelihood of approval of a Phase I hematologic asset is 9.3%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for MCL have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.

The US has a substantial lead in the number of MCL clinical trials globally. France and Germany lead the major European markets, while China has the top spot in Asia.

Johnson & Johnson has the highest number of completed clinical trials for MCL, with 15 trials. Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for MCL, followed by Bristol Myers Squibb.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis
TREATMENT
  • Targeted therapies
  • Chemotherapies
  • Steroids
  • Immunomodulators
  • Radiation therapy
  • Proteasome inhibitors
  • Stem cell transplantation
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION
  • Cirmtuzumab for MCL (December 7, 2020)
  • Parsaclisib for MCL (December 6, 2020)
  • Breyanzi for MCL (December 5, 2020)
  • LOXO-305 for MCL (December 5, 2020)
  • Tecartus for MCL (December 9, 2019)
  • LOXO-305 for MCL (December 8, 2019)
  • Copiktra for MCL (July 25, 2019)
KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Krka, Accord And Xeris Pick Up European Nods
  • Kite’s Tecartus PRIMEd For EU Market With CHMP Nod
  • Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
  • Deals Shaping The Medical Industry, January 2020
REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY
  • Prescription information
APPENDIX

LIST OF FIGURES
Figure 1: Global trends in incident cases of MCL, 2017-26
Figure 2: Global incident cases of MCL, by age, 2017
Figure 3: Overview of pipeline drugs for MCL in the US
Figure 4: Pipeline drugs for MCL, by company
Figure 5: Pipeline drugs for MCL, by drug type
Figure 6: Pipeline drugs for MCL, by classification
Figure 7: Cirmtuzumab for MCL (December 7, 2020): Phase Ib/II - CIRLL Study
Figure 8: Breyanzi for MCL (December 5, 2020): Phase I - TRANSCEND
Figure 9: LOXO-305 for MCL (December 5, 2020): Phase I/II - BRUIN
Figure 10: Tecartus for MCL (December 9, 2019): Phase II - ZUMA-2 (r/r MCL)
Figure 11: Key upcoming events in MCL
Figure 12: Probability of success in the hematologic pipeline
Figure 13: Clinical trials in MCL
Figure 14: Top 10 drugs for clinical trials in MCL
Figure 15: Top 10 companies for clinical trials in MCL
Figure 16: Trial locations in MCL
Figure 17: MCL trials status
Figure 18: MCL trials sponsors, by phase

LIST OF TABLES
Table 1: Global incident cases of MCL, 2017-26
Table 2: Global incident cases of MCL, by gender, 2017
Table 3: Marketed drugs for MCL
Table 4: Pipeline drugs for MCL in the US
Table 5: Cirmtuzumab for MCL (December 7, 2020)
Table 6: Parsaclisib for MCL (December 6, 2020)
Table 7: Breyanzi for MCL (December 5, 2020)
Table 8: LOXO-305 for MCL (December 5, 2020)
Table 9: Tecartus for MCL (December 9, 2019)
Table 10: LOXO-305 for MCL (December 8, 2019)
Table 11: Copiktra for MCL (July 25, 2019)
Table 12: Historical global sales, by drug ($m), 2015-19
Table 13: Forecasted global sales, by drug ($m), 2021-25
Note: Product cover images may vary from those shown
Adroll
adroll